# The use of endogenous T cells for adoptive transfer

Source: https://onco.cc/key-papers/paper-yee-endogenous-t-cells-immunol-rev-2014/  
OnCo record `paper-yee-endogenous-t-cells-immunol-rev-2014` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A review of how T cells already present in a patient's blood or tumour can be found, grown and made to work better as a cancer treatment.

## Summary

The review presents endogenous T cells derived from peripheral blood or tumour sites as a source of effector cells for adoptive therapy, and covers strategies to isolate, manipulate and enhance antigen-specific T cells in vitro and to improve their efficacy and persistence in vivo by host immunomodulation (Immunological Reviews 2014).

## Fields

- Kind: Key paper
- Last checked: 2026-11-05
- Journal: Immunological Reviews
- Year: 2014
- DOI: 10.1111/imr.12134
- Authors: Yee C.
- Findings: Reviews methods to isolate, expand and enhance antigen-specific endogenous T cells and to improve their persistence after transfer.
- What it means: An overview of the endogenous T-cell approach from one of its developers, written as checkpoint inhibitors and engineered cell therapies were entering the clinic.
- Caveats: Narrative review; no new data.

## Sources

- DOI 10.1111/imr.12134: https://doi.org/10.1111/imr.12134
- PubMed 24329802: https://pubmed.ncbi.nlm.nih.gov/24329802/

## Connected records

- terms: [Endogenous T-cell therapy](https://onco.cc/terms/endogenous-t-cell-therapy/)
- people: [Cassian Yee](https://onco.cc/people/cassian-yee/)

---
JSON: https://onco.cc/api/v1/entities/paper-yee-endogenous-t-cells-immunol-rev-2014.json